SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.02
−0.49%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.04
From 52W high−14.77%
Volume42997.00
Market cap$111.85M
P/E (TTM)—
P/S (TTM)8.1x
Div yield—
Key dataOct 19, 2026
Open
$2.04
From 52W high
−14.77%
Volume
42997.00
Market cap
$111.85M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
45.5
MomentumView details →
1D Return
−0.49%
YTD Return
+10.66%
SummaryUpdated Jun 1, 2026
Seer, Inc. (NASDAQ:SEER) is a life sciences company founded in 2017 and headquartered in Redwood City, California. The company went public in December 2020 and specializes in developing and commercializing advanced proteomics technology to help researchers decode the complexities of the human proteome. Seer has positioned itself as a pioneer in deep, unbiased proteomics analysis at scale, serving over 135 customers across 20 countries through its flagship Proteograph Product Suite.
Similar companies
Latest newsMore news →
Seer, Inc. announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K proteomics study at the 2026 HUPO World Congress in Singapore.26d agoDavid Horn resigned as President, Chief Financial Officer and Treasurer of Seer, Inc., effective October 1, 2026.31d ago